Lung cancer is a disease in which the cells of the lung tissues grow uncontrollably and form tumors. There are two kinds of lung cancers, primary and secondary. Primary lung cancer (also called adenocarcinoma) starts in the lung itself. Primary lung cancer is divided into small cell lung cancer and non-small cell lung cancer, depending on how the cells look under the microscope. Secondary lung cancer is cancer that starts somewhere else in the body (for example, the breast or colon) and spreads to the lungs.
Breathalyzer Test May Detect Deadliest Cancer — Researchers from TAU and partner institutions develop groundbreaking device that spots lung cancer – to stop it in its tracks – A new device developed by a team of Israeli, American, and British cancer researchers may turn the tide by both accurately detecting lung cancer and identifying its stage of progression.
Final recommendations on lung cancer screening — Final word: Task Force says screen high-risk populations for lung cancer – High-risk adults between the ages of 55 and 80 should receive annual lung cancer screening with low-dose computed tomography, according to final recommendations from the U.S. Preventive Services Task Force being published in Annals of Internal Medicine.
Lung cancer mortality rates among young and middle-aged white women climb in some states — New analysis points to tobacco control efforts or lack thereof as likely cause – A new study comparing lung cancer mortality rates among women by year of birth shows dramatic differences in trends between states, likely reflecting the success or failure of tobacco control efforts. The study finds that while lung cancer mortality rates declined continuously by birth year for women born after the 1950s in California, rates in other states declined less quickly or even increased.
Adding drug to standard chemotherapy provides no survival benefit for older lung cancer patients – Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) ? an approach approved by the FDA in 2006 ? did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare.
Common postoperative radiotherapy does not improve survival in older people with lung cancer – Post-operative radiation therapy (PORT), a controversial yet frequently administered treatment for lung cancer, may not prolong life in older people with locally advanced disease.
New lung cancer test predicts survival — Clinical studies in US and China show molecular test could more accurately guide treatment for people with lung cancer – In the two largest clinical studies ever conducted on the molecular genetics of lung cancer, an international team led by scientists at the University of California, San Francisco (UCSF) has demonstrated that an available molecular test can predict the likelihood of death from early-stage lung cancer more accurately than conventional methods.
Lung cancer screening trial shows screening with CT scans reduces lung cancer deaths – Scientists have found a 20 percent reduction in deaths from lung cancer among current or former heavy smokers who were screened with low-dose helical computed tomography (CT) versus those screened by chest X-ray. The primary research results from the National Lung Screening Trial (NLST) were published in the New England Journal of Medicine.
Gene expression changes in nasal cells may help identify lung cancer in earliest stages – A simple, minimally-invasive technique using cells from the interior of the nose could help clinicians detect lung cancer in its earliest – and most treatable – stages, according to a study conducted by researchers in Boston.
Higher levels of vitamin B6, common amino acid associated with lower risk of lung cancer – An analysis that included nearly 400,000 participants finds that those with higher blood levels of vitamin B6 and the essential amino acid methionine (found in most protein) had an associated lower risk of lung cancer, including participants who were current or former smokers.
AE-941, a standardized shark cartilage, does not improve lung cancer survival – The anti-cancer drug AE-941, a shark cartilage derivative, did not improve overall survival in patients with inoperable stage III non-small cell lung cancer, according to a study published online May_26 in the Journal of the National Cancer Institute.